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Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the 
nuclear receptor superfamily. It functions as a ligand-activated transcription 
factor and plays important roles in the regulation of adipocyte differentiation, 
type 2 diabetes mellitus, and inflammation. Many PPARγ agonists bind to 
the canonical ligand-binding pocket near the helix H12. More recently, an 
alternate ligand-binding site of the PPARγ ligand-binding domain (LBD) 
was identified; it is located beside the Ω loop between the helices H2´ and 
H3. Previously it was reported that the chirality of two optimized 
enantiomeric PPARγ ligands (S35 and R35) differentiates their PPARγ 
transcriptional activity, binding affinity, and inhibitory activity toward Cdk5 
(cyclin-dependent kinase 5)-mediated phosphorylation of PPARγ at Ser273. 
S35 is a PPARγ phosphorylation inhibitor with promising glucose uptake 
potential, while R35 behaves as a potent conventional PPARγ agonist. To 
provide a structural basis for understanding the differential activities of these 
ligands, I have determined crystal structures of the PPARγ LBD in complex 
with either S35 or R35. These structural data reveal a significant difference 
in the binding modes of these enantiomeric ligands to the PPARγ LBD. S35 
 ii
occupies the alternate ligand-binding site, whereas R35 binds to the 
canonical ligand-binding pocket, thus explaining their different behaviors as 
PPARγ agonists. This finding provides a useful platform for the 
development of a new generation of PPARγ ligands as anti-diabetic drug 
candidates.  
 
Helicobacter pylori infection is one of the highest risk factors for 
gastroduodenal diseases including gastric cancer. Tumor necrosis factor-α 
(TNF-α) is one of the essential cytokines for tumor promotion and thus a H. 
pylori protein that induces TNF-α is believed to play a significant role in 
gastric cancer development in humans. The HP0596 gene product of H. 
pylori strain 26695 was identified as the TNF-α inducing protein (Tipα). 
Tipα is secreted from H. pylori as dimers and enters the gastric cells. It was 
shown to have a DNA binding activity. Here I have determined the crystal 
structure of Tipα from H. pylori. Its monomer consists of two structural 
domains (“mixed domain” and “helical domain”). Tipα exists as a dimer in 
the crystal and the dimeric structure represents a novel scaffold for DNA 
binding. A positively-charged surface patch formed across the two 
monomers of the Tipα dimer by the loop between helices α1 and α2 may be 
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Structural basis for differential transcription activation by 










Peroxisome proliferator-activated receptors (PPARs) are a group of 
ligand-activated transcription factors that belongs to the thyroid hormone 
receptor-like nuclear receptor (NR) subfamily 1 (Gallastegui et al., 2015). 
PPARs bind to cognate peroxisome proliferator response elements (PPREs) 
through hetero-dimerization with retinoid X receptors (RXRs) and regulate 
the transcription of target genes (Berger and Moller, 2002). Among three 
known mammalian PPAR subtypes (PPARα, PPARγ, and PPARδ/) that 
show distinct ligand specificity and tissue distribution, PPARγ is highly 
expressed in adipocytes and macrophages (Tontonoz et al., 1994; Ricote et 




homeostasis, lipid metabolism, insulin sensitization, and inflammatory action 
(Lehrke and Lazar, 2005). Thus, PPARγ is a potential therapeutic target for 
metabolic syndrome and inflammatory diseases such as type 2 diabetes and 
atherosclerosis (Walczak and Tontonoz, 2002; Waku et al., 2010). 
Like other nuclear receptors, PPARγ contains an N-terminal domain 
(NTD), a DNA-binding domain (DBD), a hinge region, and a ligand-binding 
domain (LBD). The LBD of PPARγ is comprised of 12 α-helices in a three-
layer sandwich and a small four-stranded β-sheet. The canonical ligand-
binding pocket (LBP) of PPARγ is a Y-shaped hydrophobic cavity within 
the 12 helix-bundle of LBD. Its volume is in the range of 1,200-1,450 Å3, 
which is much larger than those of most other nuclear receptors (Gallastegui 
et al., 2015; Nolte et al., 1998; Waku et al., 2010). In the apo form of the 
PPARγ LBD, helix 12 (H12), a highly flexible switch element, is in a state 
of equilibrium among many different conformations varying from active to 
inactive (Kallenberger et al., 2003). Binding of PPARγ agonists in the 
canonical LBP induces conformational changes in the LBD via the formation 
of a hydrogen bond network that stabilizes H12 (Nolte et al., 1998). Binding 
of agonists also affects the recruitment of coactivators (Nolte et al., 1998) or 
corepressors (Hu et al., 2001), which is a key mechanism for modulating 




alternate ligand-binding site was identified in the LBD of PPARγ adjacent to 































The canonical LBP of PPARγ can accommodate a multitude of 
endogenous and synthetic ligands and also simultaneously more than one 
PPARγ ligand (Bruning et al., 2007; Xu et al., 2008; Loiodice et al., 2011; 
Hughes et al., 2014). The large ligand-binding pocket of PPARγ is likely to 
have a role in its biology by allowing the receptor to perceive not only a 
single ligand but rather a pool of related ligands (Waku et al., 2010; Itoh et 
al., 2008). This means that the concentration of this pool of ligands is likely 
to be more relevant than the concentration of each individual ligand, making 
PPARγ a sensor of oxidized fatty acids (Itoh et al., 2008).  
Synthetic ligands of PPARγ include a class of insulin-sensitizing anti-
diabetic drugs referred to as thiazolidinediones (TZDs), such as rosiglitazone 
and pioglitazone, and the GW series of L-tyrosine analogs (Ambrosio et al., 
2007). Despite the clinical benefit of TZDs, their use has been associated 
with adverse effects, including weight gain, increased adipogenesis, renal 
fluid retention, plasma volume expansion and possible increased incidences 
of cardiovascular events (Berger et al., 2005; Nissen and Wolski, 2007; 
Bruning et al., 2007). Rosiglitazone and pioglitazone, PPARγ TZD full 
agonists, are structurally similar but afford different clinical adverse events. 
It indicates that subtle changes in the ligand-receptor interaction can lead to 




importance of the need for a more complete understanding of the mechanism 
of PPARγ modulation by synthetic ligands (Bruning et al., 2007). 
It was reported that synthetic PPARγ ligands exert another biochemical 
function by blocking the phosphorylation of PPARγ at Ser273 by cyclin-
dependent kinase 5 (Cdk5) (Choi et al., 2010). The phosphorylation of 
PPARγ does not alter its adipogenic capacity but leads to dysregulation of 
the genes whose expression is altered in obesity, including lowered 
expression of the insulin-sensitizing adipokine, adiponectin (Choi et al., 
2010). The Cdk5-mediated phosphorylation of PPARγ is blocked by anti-
diabetic PPARγ ligands, such as rosiglitazone (a full agonist) and MRL24 (a 
partial agonist) (Choi et al., 2010). Inhibition of PPARγ phosphorylation in 
obese patients by rosiglitazone is very tightly associated with the anti-
diabetic effects of this drug (Choi et al., 2010). We previously identified two 
optimized enantiomeric PPARγ ligands (R35 and S35) and reported that the 
chirality of these enantiomeric ligands differentiates their PPARγ 
transcriptional activity, binding affinity, and inhibitory activity toward Cdk5-
mediated phosphorylation of PPARγ at Ser273. S35, a partial agonist of 
PPARγ, shows an inhibitory activity toward Cdk5-mediated phosphorylation 




enantiomer R35 is a highly potent conventional PPARγ agonist (Koh et al., 
2014 Angew. Chem. Int. Ed.). 
To provide a structural basis for understanding their differential 
activities, we have determined crystal structures of the PPARγ LBD in 
complex with either S35 or R35. Unexpectedly, these enantiomeric ligands 
bind to the PPARγ LBD in significantly different manners. The partial 
agonist S35 occupies the alternate site near the Ω loop, whereas the full 
agonist R35 binds entirely to the canonical LBP near the helix H12. The 
flexible Ω loop region is stabilized by the binding of S35 in the alternate site. 
The S35-bound PPARγ LBD simultaneously accommodates a fatty acid 
(modeled here as myristate) in the canonical LBP. In contrast, the fatty acid 
binding is prohibited by the binding of R35 to the PPARγ LBD. This study 
shows that different binding modes of S35 and R35 in the PPARγ LBD 
determine their differential behaviors as PPARγ agonists. This finding may 








1.2. Material and methods 
 
1.2.1. Protein expression and purification 
The gene encoding the human PPARγ LBD construct (residues 195–477 
in PPARγ1 numbering) was PCR-amplified using a human cDNA clone 
encoding PPARγ (clone ID: hMU000317) as the template, which was 
provided by the Korea Human Gene Bank, Medical Genomics Research 
Center, Korea Research Institute of Bioscience & Biotechnology. It was 
cloned into the expression vector pET-28b(+) (Novagen). This construct of 
the recombinant protein encodes a 21-residue N-terminal tail 
(MGSSHHHHHH SSGLVPRGSH M) containing a His6 tag and a thrombin 
cleavage site in front of the starting residue Ala195 (PPARγ1 numbering). 
The recombinant human PPARγ LBD was overexpressed in Escherichia coli 
Rosetta 2(DE3) cells using the Luria Broth culture medium. Protein 
expression was induced by 0.5 mM isopropyl -D-thiogalactopyranoside and 
the cells were incubated for additional 24 h at 18C following growth to 
mid-log phase at 37C. The cells were lysed by sonication in buffer A [20 
mM Tris-HCl at pH 8.5, 150 mM NaCl, 10% (v/v) glycerol and 0.1 mM 
tris(2-carboxyethyl) phosphine hydrochloride] containing 5 mM imidazole 




at 36,000 g for 1 hr. The supernatant was applied to a HiTrap Chelating HP 
affinity chromatography column (GE Healthcare), which was previously 
equilibrated with buffer A containing 5 mM imidazole. Upon eluting with a 
gradient of imidazole in the same buffer, the human PPARγ LBD was eluted 
at 45100 mM imidazole concentration. The eluted protein was desalted in 
buffer A by HiPrep 26/10 desalting column (GE Healthcare) to remove 
imidazole, and the protein was cleaved with 2 units of thrombin (Sigma 
Aldrich) per mg of the PPARγ LBD at 4C overnight. Both the N-terminal 
fusion tag and the uncleaved protein were removed by affinity 
chromatography with a HiTrap Chelating HP affinity chromatography 
column. The flow-through was applied to a HiLoad XK-16 Superdex 200 
prep-grade column (GE Healthcare), which was previously equilibrated with 
buffer A. Fractions containing the human PPARγ LBD were pooled and 
concentrated to 15.4 mg ml-1 using an Amicon Ultra-15 Centrifugal Filter 
Unit (Millipore). 





Before crystallization, the purified PPARγ LBD and a LXXLL motif-
containing peptide derived from human steroid receptor coactivator-1 (SRC1) 
(residues 685700, ERHKILHRLLQEGSPS) were mixed in a molar ratio of 
1:2, in the presence or absence of a 10-fold molar excess of the PPARγ 
ligand S35 or R35. After overnight incubation, the protein-ligand complexes 
were crystallized by the sitting-drop vapor diffusion method using the 
Mosquito robotic system (TTP Labtech) at 23C by mixing 0.2 l of the 
protein solution and 0.2 l of the reservoir solution. The PPARγ·SRC1 
crystals (Figure 1-2) and the PPARγ·S35·SRC1 crystals were obtained with 
a reservoir solution of 2.2 M sodium malonate at pH 7.0. The initial 
PPARγ·S35·SRC1 crystals appeared as multiple crystals that were not 
suitable for diffraction and, therefore, microseeding technique was used to 
obtain single crystals. Several pieces of the crystals were transferred into an 
Eppendorf tube containing a Seed Bead (Hampton Research) and 50 µl 
stabilization solution of 2.2 M sodium malonate at pH 7.0, and were 
vortexed to produce microseeds. The stock solution of microseeds was then 
briefly centrifuged and diluted serially by a factor of 1001000 in the same 




solution, the reservoir solution, and the microseed solution in a volume ratio 
of 1:0.7:0.3. Single crystals (Figure 1-3) grew reproducibly to dimensions of 
approximately 0.35 × 0.2 × 0.1 mm within a few days. The 
PPARγ·R35·SRC1 crystals (Figure 1-4) were obtained with a reservoir 
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1.2.3. X-ray data collection, structure determination, and refinement  
All sets of X-ray diffraction data except for the S35-bound PPARγ LBD 
were collected at 100 K using a Quantum Q270 CCD detector system (Area 
Detector Systems Corporation, Poway, California) at the BL-7A 
experimental station of Pohang Light Source, Korea. The X-ray data from 
the crystal of S35-bound PPARγ LBD were collected at 100 K using a 
Quantum 315r CCD detector system (Area Detector Systems Corporation, 
Poway, California) at the BL-5C experimental station of Pohang Light 
Source, Korea. Raw X-ray diffraction data were processed and scaled using 
the program suit HKL2000 (Otwinowski and Minor, 1997). Data collection 
statistics are summarized in Table 1-1. All structures were solved by 
molecular replacement with the program MolRep (Vagin and Teplyakov, 
2010) using the previously published PPARγ LBD structure (PDB code, 
3VN2; Amano et al., 2012) as a search model. Subsequent model building 
was done manually using the program COOT (Emsley et al., 2010) and the 
models were refined with the program REFMAC5 (Murshudov et al., 1997), 
including the bulk solvent correction. A total of 5% of the data was 
randomly set aside as test data for the calculation of Rfree (Brünger et al., 










 Table 1-1. Data collection statistics 
 
 
Footnotes to Table 1-1 
a Values in parentheses refer to the highest resolution shell. 
b Rmerge = hi  I(h)i – <I(h)>  / hi I(h)i, where I(h) is the intensity of 
reflection h, h is the sum over all reflections, and i is the sum over i 





Model name Agonist-free S35-bound R35-bound 
X-ray wavelength (Å) 0.9793 1.0000 1.0000 
Space group P21212 P21212 P21212 
Unit cell parameters 
a (Å) 131.31 131.82 131.65 
b (Å) 53.06 53.29 52.45 
c (Å) 53.55 53.74 54.29 
 =  =  () 90 90 90 







Total / unique reflections 94,500 / 16,193 128,674 / 22,810 156,963 / 32,794 
Completeness (%) 99.4 (100.0)a 99.5 (100.0)a 99.7 (100.0)a 
<I> / <I> 36.2 (4.0)a 41.1 (3.6)a 39.5 (3.0)a 
Rmerge




Table 1-2. Refinement statistics 
 
 
Footnotes to Table 1-2 
a Rwork =  | |Fobs| – |Fcalc| | /  |Fobs|, where Rfree is calculated for a randomly 
chosen 5% of reflections, which were not used for structure refinement and 
Rwork is calculated for the remaining reflections. 
b Values in parentheses refer to the average B factor of myristate. In the case 
of R35, myristate binding is blocked by R35. For other data, extra electron 
Model refinement 
Mocdel name Agonist-free S35-bound R35-bound 
Resolution range (Å) 30–2.35 30–2.10 30–1.85 
Rwork / Rfree
a (%) 21.1 / 25.7 21.2 / 24.2 20.6 / 22.8 
No. of non-hydrogen atoms 
 Protein 2,196 2,245 2,260 
 Ligand 22 67 45 
 Water oxygen 45 108 211 
Average B factor (Å2) 
 Protein 68.0 54.7 39.0 
 Ligand 96.6 (99.8)b 77.2 (78.9)b 29.3 (-)b 
 Water oxygen 59.4 56.6 44.9 
R.m.s. deviations from ideal geometry 
 Bond lengths (Å) 0.012 0.011 0.011 
 Bond angles () 1.49 1.49 1.48 
Ramachandran plotc 
 Favored / Outliers (%) 97.4 / 0 98.2 / 0 99.3 / 0 




density was modeled as myristate. 






1.2.4. In vitro kinase assay 
In vitro Cdk5 assay was conducted according to the manufacturer’s 
instruction (Cell Signaling Technology). Briefly, 0.5 μg of the purified 
PPARγ LBD was incubated with active Cdk5/p35 (Millipore) in assay buffer 
(25 mM Tris-HCl at pH 7.5, 5 mM β-glycerophosphate, 2 mM dithiothreitol, 
0.1 mM Na3VO4, 10 mM MgCl2) containing 25 μM ATP for 30 min at 30°C. 
S35 and R35 were pre-incubated with the PPARγ LBD for 30 min at 30°C 
before performing the assay. The Rb-peptide (residues 773928, Millipore) 
was also used as a substrate of Cdk5 to test whether the compounds affect 
the kinase activity of Cdk5 or not. Phosphorylation of the Cdk5 substrates 
was analyzed by Western blotting with an anti-Cdk substrate antibody to 
detect phospho-Ser in a K/R-S-P-K/R motif, which is the consensus motif 




1.2.5. Cell-based luciferase reporter gene assay 
The transcriptional activity of human PPARγ was determined by 
measuring the luciferase activity in PPARγ reporter assays (Indigo 
Biosciences, State College, PA) according to the manufacturer’s instruction. 
The reporter cells, derived from Chinese hamster ovary cells, constitutively 
express human hybrid PPARγ. These reporter cells incorporate a responsive 
luciferase reporter gene and quantifying expressed luciferase activity 
provides a sensitive detection of PPARγ activity in the system. Briefly, 100 
µl of human PPARγ reporter cell suspensions was dispensed into the wells of 
96-well assay plates and 100 µl of test compounds was added to the 
respective wells in triplicates. Plates were transferred into a 37°C, 
humidified 5% CO2 incubator for 22 h. Control cells were treated with 0.1% 
(v/v) DMSO in a compound-screening medium. For studies involving the 
covalent antagonist GW9662, before incubation with PPARγ ligands S35 
and rosiglitazone, cells were first pre-incubated with 5 µM GW9662 for 3 h. 
At the end of the treatment, the medium was discarded and 100 µl of 
Luciferase Detection Reagent was added to each well of the assay plate. The 
reaction mixture was incubated for 15 min at room temperature and 




Bio-Tek Instruments Inc.). Fold changes of treated cells over DMSO-treated 









1.3.1. Overall structure of the PPARγ LBD and structural comparisons 
Here I have solved the crystal structures of the PPARγ LBD complexed 
with either S35 or R35 (Figure 1-5) in the presence of a peptide derived from 
the human steroid receptor coactivator-1 (SRC1) coactivator protein. I have 
also solved the agonist-free structure of the PPARγ LBD in the presence of 
the SRC1 coactivator peptide. The structures reveal the canonical nuclear 
receptor fold, comprised of three-layered antiparallel α-helices and a four-
stranded β-sheet. The C-terminal activation function-2 (AF-2) helix (H12) 
exists in the active conformation. The LXXLL motif of SRC-1 coactivator is 
in a helical conformation and is bound in the hydrophobic cleft between the 
charge clamp, which is formed by Glu471 and Lys301 on the surface of the 
PPARγ LBD (Figure 1-6A) (Nolte et al., 1998). The structures of the PPARγ 
LBD complexed with either S35 or R35 are very similar to that of the 
agonist-free structure, with an r.m.s. deviation of 0.49 Å or 0.58 Å for 261 
Cα atom pairs. The r.m.s. deviation between the structures of the two 
complexes is slightly larger (1.01 Å for 265 Cα pairs) (Figure 1-6B). 




Lys261 and Thr268, which belong to the flexible Ω loop. This region is 
reasonably well-defined by the electron density in both complexes and the 
observed large structural difference around this region is a consequence of 
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PPARγ2). Only the Ω loop of S35-bound LBD is colored in violet. Agonist 








1.3.2. S35 occupies the alternate ligand binding site in the PPARγ LBD  
The electron density of S35 in the PPARγ ligand binding pocket is 
interrupted at the central moiety of the molecule, but it is generally well 
defined (Figure 1-7A and 1-8A). Recently Hughes et al. reported the 
alternate ligand-binding site of the PPARγ LBD which was previously 
irrelevant to the ligand binding. Interestingly, S35 is bound to the alternate 
ligand-binding site by wrapping around helix 3, and is surrounded by β-sheet 
and the Ω loop. A comparison between structures of S35 and rosiglitazone 
(2PRG) complexes revealed that a small portion of the molecules is 
overlapped. And also S35 is located in the opposite direction compared with 
the R counterpart and the dimethoxyphenyl ring and the carbamoyl group of 
the two enantiomers are overlapped with each other (Figure 1-9). S35 is far 
from the canonical ligand-binding pocket and shows no direct hydrogen 
bond interactions with the AF2 helix. The interactions between the PPARγ 
LBD and S35 involve two hydrogen bonds and some hydrophobic 
interactions (Figure 1-7B). The carboxylate group of S35 participates in 
hydrogen bonds. One of the carboxylate oxygens forms a hydrogen bond 
with the backbone amino group of Leu270 with a distance of 2.67 Å2. The 
other carboxylate oxygen is also hydrogen bonded with the Nε2 atom of 




the LBD can be divided into two groups. The first group is formed by the 
interactions to the the dimethoxyphenyl ring. This moiety occupies the space 
between helix 3 and β-sheet, which formed by residues of Ile281, Leu340, 
Ile341, and Met364. The second group is made up of interactions between 
the other parts of S35 and the LBD. This moiety is located in the alternate 
ligand-binding site of the LBD formed by residues Leu255, Gln259, Ile262, 
Phe264, Ile267, Thr268, Pro269, Arg280, Gly284, Phe287, and Ser342. We 
have observed the S35-bound PPARγ LBD structure and found two extra 
electron densities. The one is located near the AF2 helix. This region was 
occupied by the thiazolidinedione group in the rosiglitazone-bound structure. 
We assume that this electron density is a glycerol molecule comes from 
protein purification step. The other is placed between the helices 3 and 5 
(Figure 1-10A). We guess that the second electron density is a long-chain 
fatty acid (Myristate) simultaneously bound in the PPARγ LBD as previous 
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LIGPLOT. Hydrogen bonds are depicted by dashed lines, hydrophobic 
interactions are indicated by spoked arcs, and atoms with spokes. Oxygen 
atoms are colored red, nitrogen atoms blue, and carbon atoms grey. β: β-
sheet (green). H: helix (cyan). Residue numbers correspond to PPARγ 
isoform 1. Hydrogen bonds are labeled with donor–acceptor distances in 
angstrom. (C) Ribbon diagram of the R35-bound PPARγ LBD (pale cyan) 
with the SRC1 coactivator peptide (grey). The conventional strong agonist 
R35, shown as a ball and stick model in cyan, binds to the canonical LBP of 
PPARγ LBD. The electron density for R35 in the omit mFo – DFc map is 
shown in wheat colored mesh (contoured at 2.0σ). The phosphorylation site 
at Ser245 (red) is represented by sticks. (D) Schematic representation of the 
interactions between the PPARγ LBD and R35, as calculated using 
LIGPLOT. Hydrogen bonds are depicted by dashed lines, hydrophobic 
interactions are indicated by spoked arcs, and atoms with spokes. Oxygen 
atoms are colored red, nitrogen atoms blue, and carbon atoms grey. β: β-
sheet (green). H: helix (cyan). Residue numbers correspond to PPARγ 
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the R35-bound PPARγ LBD (pale cyan) with SRC1 coactivator peptide 
(grey). The secondary structure elements are labeled. Amino acid residues 
Ile267 and Thr268 of the Ω loop are shown as sticks, with the 2mFo – DFc 
electron density map (violet) contoured at 1.0σ. The electron density for the 
conventional strong agonist R35 in the omit mFo – DFc map is also shown 







1.3.3. Ligand binding cavity of the PPARγ LBD in S35-bound structure 
The ligand-binding pocket of the PPARγ LBD from the structure of S35 
complex is a large Y-shaped cavity with a volume around 1560 Å3 with three 
arms (Figure 1-11A). The left arm of the Y is composed of a mix of 
hydrophobic residues (Phe282, Ile326, Tyr327, Leu330, Val339, Leu353, 
Leu356, Phe360, Phe363, Met364, and Leu453) and polar residues (Cys285, 
Gln286, Ser289, His323, Lys367, and His449) and is covered by three 
residues from the AF-2 helix (Leu469 and Tyr473) and the loop between 
helices 11 and 12 (Leu465). The right arm of the Y is also formed by a mix 
of hydrophobic residues (Phe226, Pro227, Leu228, Ile296, Ile325, Met329, 
Leu333, Leu340, and Leu384) and polar residues (Arg288, Glu291, Glu395, 
Ser332, Glu343, and Asp381). The third arm of the Y-shaped pocket from 
the structure of S35 complex is extended beyond the alternate ligand-binding 
site which is approximately 200 Å3 in volume. The third arm is composed of 
the hydrophobic residues Ile249, Leu255, Ile262, Phe264, Ile281, Ile341, 
and Met 348 and several polar residues Glu259, Arg280, and Ser342. The 
alternate ligand-binding site region is surrounded by the residues from helix 
3 (Gln283 and Phe287) and the Ω loop between helices 2' and 3 (Ile267, 
Pro269, Leu270, and Lys275) (Figure 1-11A). One hundred twenty seven 




ligands that were taken from the PDB in February 2016 aligned with the 
S35-bound PPARγ LBD structure, all ligands were included in the Y-shaped 
pocket and S35 only occupied the alternate ligand-binding site (Figure 1-
11B). As aforementioned, the presence of S35 inside the alternate ligand-
binding site appears to induce a unique and stable conformation of the Ω 
loop, when compared with other published structures. Interestingly, the 
phenoxy ring of S35 forms a stacking interaction with two residues from 
helix 3 (Phe287) and the Ω loop (Pro269) (Figure 1-10A). In addition, from 
the B-factor analysis compared between S35-bound and Agonist-free, we 







Figure 1-11. Ligand binding cav
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(A) Ribbon diagram of S35-bound PPARγ LBD, with its ligand binding 
cavity shown as a surface and colored in pale green for the canonical LBP 
and in warm pink for the alternate binding site. The canonical Y-shaped 
cavity (pale green) has three arms and the alternate binding cavity (warm 
pink) extends from the base of Y. The cavity is calculated by the KVFinder 
program (Oliveira et al. 2014) using the values of step size (0.6 Å), probe in 
size (1.4 Å), and probe out size (4.5 Å). The total volume of the ligand 
binding cavity is approximately 1,560 Å3, including the alternate binding site 
(200 Å3). (B) Superposition of S35 and other reported PPARγ·ligand 
complexes with its ligand binding cavity in two different orientations. The 
ligand S35 (colored in green) occupies the alternate binding site of the 
PPARγ LBD, which is unique compared to many other previously-reported 
PPARγ ligands (colored in blue). The canonical ligand-binding cavity 
(colored in pale green) encompasses nearly all other PPARγ ligands except a 
few ligands. (A) S35 shown in sticks (green) with electron density in light 











































1.3.4. R35 binds to the canonical LBP in the PPARγ LBD  
The omit map calculated using the refined model revealed a clear 
electron density for R35 in the canonical LBP of the PPARγ LBD (Figure 1-
7C and 1-8B). A comparison between structures of R35 and rosiglitazone 
(2PRG) complexes revealed that both ligands adopt a U-shaped 
conformation in the PPARγ LBD and wrap around Cys285 from helix 3 to 
directly contact AF-2 helix (Figure 1-9). Molecular volumes of R35 and 
rosiglitazone are 552 Å3 and 315 Å3, respectively (calculated by the 
Molinspiration web services at http://www.molinspiration.com/services/). 
The interactions between the PPARγ LBD and R35 involve two hydrogen 
bonding networks and numerous hydrophobic interactions (Figure 1-7D). 
The carboxyl group of R35 participates in a first hydrogen bonding network. 
One of the carboxylate oxygens makes a bifurcated hydrogen bond with the 
Oη atom of Tyr473 and the Nε atom of His449 with a distance of 2.58 Å2 
and 2.81 Å2, respectively. The other carboxylate oxygen is also bifurcated 
hydrogen bonded with the Nε atom of His323 and the Oγ atom of Ser289 
with a distance of 2.77 Å2 and 2.85 Å2, respectively. The other hydrogen 
bonding network occurs in a distant area from AF-2 helix. The oxygen of 
amide group of R35 forms a water mediated hydrogen bond with the main 




R35 with the LBD can be divided into four groups. The first group is formed 
by the interactions to the methylpropanoate moiety. This moiety is 
positioned in a hydrophobic region of the LBD pocket formed by the side 
chain of Phe282, Gln286, Leu453, and Leu469. The second group is the 
asymmetric carbon, isoxazole ring and phenoxy ring. This moiety is located 
in a narrow groove of the LBD formed by residues Cys285, Leu330, Met334, 
Met364, Lys367, and Phe368. The third group of interaction is formed 
between the benzyl ring of the ligand and the side chains of residues Arg288, 
Ile326, and Leu330. The benzyl ring of R35 particularly engaged in the CH-
π interaction with the alkyl chain of Arg288 (Figure 1-10B). The forth group 
is made up of interactions between the dimethoxyphenyl ring and the LBD. 
This moiety occupies the space between helices 2' and 3 and β-sheet, which 
formed by residues of Leu255, Arg280, Ile281, Gly284, Phe287, and Ile341. 
Compared with other reported structures, both S35 and R35 stabilize the 
conformation of the Ω loop. The binding of R35 in the LBD induce the 
stable conformation of the Ω loop, although not as strong as the binding of 




1.3.5. Alternate site binding of S35 correlates with its activities 
To elucidate the effect of S35 binding to the alternate ligand-binding site 
on PPARγ transactivation, I performed a luciferase reporter gene assay to 
measure the agonistic activity in PPARγ-mediated transcription in cell. 
Rosiglitazone and S35 dispalyed concentration-dependent increases on 
PPARγ transactivation, consistent with previous reports (Koh et al., 2014). 
To further evaluate whether alternate site ligand binding can affect PPARγ 
transactivation, I conducted a reporter assay by pretreating cells with 
GW9662 before administering cells with ligand. GW9662 is a synthetic 
irreversible PPARγ antagonist that covalently binds to Cys285 (Cys285 in 
PPARγ1; Cys313 in PPARγ2) on H3 (Leesnitzer et al., 2002). This covalent 
antagonist GW9662 completely blocks the ligand engagement at the 
canonical binding pocket while not fully inhibiting alternate site binding of 
PPARγ ligands (Hughes et al., 2014). Based on the superposition of 
GW9662 (3B0R) onto the S35-bound structure, S35 exhibits no steric clash 
with GW9662 (Figure 1-13). Compared to rosiglitazone or S35, GW9662 
does not affect the agonistic activity in PPARγ-mediated transcription 
(Nakano et al., 2006). As shown in Figure 1-14A, coadministration of 
GW9662 did not affect the action of S35 on PPARγ transactivation, but 




(Hughes et al., 2014), GW9662 blocks the action of rosiglitazone at 
concentration up to ~2.5 μM, whereas higher rosiglitazone concentrations 
have the agonistic activity on PPARγ transactivation (Figure 1-14A).  
I next performed in vitro Cdk5 assay to determine whether S35 binding 
to the alternate binding site can affect the Cdk5-mediated phosphorylation at 
Ser273 of PPARγ. GW9662 does not inhibit Cdk5-mediated phosphorylation 
of PPARγ at 10 μM in vitro. In the absence of GW9662 both rosiglitazone 
and S35 effectively blocked the Cdk5-mediated phosphorylation of PPARγ 
in vitro. However, coadministration of GW9662 completely blocked the 
inhibitory effect of rosiglitazone on PPARγ phosphorylation, but does not 
affect the inhibition of PPARγ phosphorylation by S35 (Figure 1-14B). As 
previous reports, neither Rosiglitazone nor S35 blocked Cdk5-mediated 
phosphorylation of the Rb protein, a known substrate of Cdk5. This 
indicated that rosiglitazone and S35 do not affect the fundamental kinase 
function of Cdk5 but block the phosphorylation of PPARγ selectively and 



















































Figure 1-14. The effect of S35 binding to the alternate binding site.  
(A) Luciferase reporter assay showing the concentration-dependent effects of 
S35 and rosiglitazone on PPARγ transactivation without GW9662 
pretreatment and with GW9662 pretreatment, performed in triplicate and fit 
to a sigmoidal dose response curve. Error bars represent the standard 
deviation around the mean value (n = 3). Rosi, rosiglitazone. (B) In vitro 
Cdk5 assay on PPARγ treated by rosiglitazone or S35 with or without 
GW9662. pPPARγ, phosphorylated PPARγ; Rosi, rosiglitazone. (C) In vitro 
Cdk5 assay on Rb-peptide upon treatment with rosiglitazone or S35. pRb-








The canonical ligand-binding pocket (LBP) of PPARγ is a Y-shaped 
hydrophobic cavity with a volume of around 1,200-1,450 Å3. This is much 
larger than those of most other nuclear receptors. Almost the whole ligands 
of the PPARγ, which were reported so far, are included in this Y-shaped 
pocket and affect on the PPARγ activation. Recent NMR study reported that 
the PPARγ LBD has the alternate ligand-binding site that encompasses an 
area not thought of as part of the Y-shaped pocket of PPARγ (Hughes et al., 
2014). This work is a unique study to identify the alternate ligand-binding 
site of the PPARγ LBD through the crystal structure. The LBP of the PPARγ 
LBD from the structure of S35 complex is a large cavity with a volume 
around 1,560 Å3 and the volume of the alternate ligand-binding site is 
approximately 200 Å3. The alternate ligand-binding site region is surrounded 
by helix 3 and the Ω loop between helices 2' and 3. S35 occupies this 
alternate ligand-binding site and and shows no direct hydrogen bond 
interactions with the AF2 helix. I observed that S35 induces concentration-
dependent increases on PPARγ transactivation with or without 
coadministered covalent antagonist GW9662 by luciferase reporter assay. 




pocket while not fully inhibiting alternate site binding of PPARγ ligands. 
Furthermore, superposition analysis between S35 and GW9662 shows that 
GW9662 exhibited no steric clash with S35; thus, S35 and GW9662 can be 
accommodated simultaneously in the LBP of PPARγ. These results 
demonstrate that S35 certainly occupies the alternate ligand-binding site and 
alternate site ligand binding of S35 can affect on the PPARγ transactivation. 
Recently, the indirect mechanism for the PPARγ agonism through the 
stabilization induced by alternate site binding was suggested (Bruning et al., 
2007; Hughes et al., 2014). The structural data in this study shows that 
alternate site binding of S35 stabilize helix3 and the Ω loop. Through the 
indirect mechanism, S35 likely affect on the PPARγ transactivation. 
However, a different explanation was suggested by observation of the 
simultaneous binding of a long-chain fatty acid in the S35-bound PPARγ 
LBP. My data and recent studies have revealed that the canonical LBP of 
PPARγ can accommodate a multitude of endogenous and synthetic ligands 
and also simultaneously more than one PPARγ ligand (Waku et al., 2010; 
Itoh et al., 2008; Puhl et al., 2012). In other word, a endogenous ligand can 
bind and functionally activate the PPARγ LBD when the alternate site is 
occupied by a synthetic ligand. This could be another mechanism of the 




canonical LBP that directly stabilize the AF-2 helix through the formation of 
hydrogen bond network with residues, including Ser289, His323, His449 and 
Tyr473. Also, the molecular volume of R35 is greater than that of 
Rosiglitazone, hence R35 has more hydrophobic interaction with the PPARγ 
LBD than Rosiglitazone. For these strong interaction, R35 likely elicits more 
robust the agonist activity of the PPARγ than Rosiglitazone (Koh et al., 2014)  
Synthetic PPARγ ligands exert PPARγ-driven anti-diabetic action by 
blocking the phosphorylation of PPARγ at Ser273 by Cdk5 that is a distinct 
mechanism from the PPARγ transcriptional activity (Choi et al., 2010). The 
phosphorylation of PPARγ does not change its adipogenic activity but leads 
to dysregulation of a specific set of genes whose expression is changed in 
obesity, including lowered expression of the insulin-sensitizing adipokine, 
adiponectin (Choi et al., 2010). The Cdk5-mediated phosphorylation of 
PPARγ is blocked by anti-diabetic PPARγ full and partial agonists (Choi et 
al., 2010). SR1664 is a compound that can block PPARγ phosphorylation at 
Ser273 and exert potent anti-diabetic activity without activation of classical 
PPARγ transcriptional agonism (Choi et al., 2011). These reports lead us to 
expect the development of novel and safer PPARγ-based antidiabetic drugs. 
However, the lack of understanding of how PPARγ activation by synthetic 




such synthetic ligands. An activator known as p25, a truncated form of the 
unstable coactivator p35, hyperactivates Cdk5 in the cellular nucleus (Shukla 
et al., 2013). Recently, a docking study reports a model for the PPARγ-
Cdk5/p25 complex and the molecular interactions between Cdk5 and PPARγ. 
This docking data suggests that an open conformation of the Ω loop enables 
the interaction between PPARγ Ω loop and Cdk5/p25 and thus the 
phosphorylation of PPARγ at Ser273 by Cdk5 occurs. But a closed 
configuration of the Ω loop induced by ligand binding to PPARγ LBP may 
prevent the PPARγ-Cdk5/p25 binding mode (Mottin et al., 2015). The 
structural data in this study also show that binding of either S35 or R35 in 
the PPARγ LBP induces the closed conformation of the Ω loop, although 
R35 is not as efficient as S35. These results suggest that alternate site 
binding of PPARγ could directly affect phosphorylation inhibition through 
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Crystal structure of the TNF-α inducing protein (Tipα) from 










Helicobacter pylori is a helical-shaped, Gram-negative bacterium that 
lives in the human stomach and duodenum. H. pylori infection is one of the 
highest risk factors for gastroduodenal diseases including gastric cancer 
(IARC working group, 1994). It has long been known that H. pylori 
infection results in an inflammatory response in the stomach by induction of 
various cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1, 
and interleukin-8 (Peek and Blaser, 2002). TNF-α is one of the essential 
cytokines for tumor promotion and thus a gene product of H. pylori that 
induces TNF-α is believed to play a significant role in gastric cancer 




Suganuma et al., 2008). The HP0596 gene product of H. pylori strain 26695 
was identified as the TNF-α inducing protein (Tipα) (Suganuma et al., 2005). 
The HP0596 gene encodes a protein of 192 amino acid residues with a signal 
peptide cleavage site between residues 20 and 21 (Suganuma et al., 2005). 
The HP0596 gene product has no sequence similarity to other virulence 
factors of H. pylori such as vacuolating cytotoxin and cytotoxin-associated 
antigen (CagA). A cell fractionation experiment indicates that Tipα is 
anchored to the inner membrane of H. pylori (Godlewska et al., 2008; 
Yoshida et al., 1999). Tipα is secreted as a homodimer of the mature 
polypeptide (residues 21–192), which contains the only two cysteines 
(Cys25 and Cys27) of Tipα in the N-terminus for the possible formation of 
inter-chain disulfide bonds (Suganuma et al., 2005) (Figure 2-1). Clinical 
isolates of H. pylori obtained from gastric cancer patients secreted the Tipα 
protein significantly more than did those from gastritis patients, suggesting 
that H. pylori Tipα is an essential factor in inflammation and carcinogenesis 
in the stomach (Suganuma et al., 2008) (Figure 2-2). Secreted Tipα binds to 
mouse gastric epithelial cells MGT-40, presumably through the action of an 
uncharacterized receptor (Suganuma et al., 2005; Suganuma et al., 2008), 
and enters those cells, resulting in the expression of TNF-α and various 




et al., 2007a). A deletion mutant of Tipα (del-Tipα; residues 28–192 fused 
with an N-terminal His tag), which lacks six residues 21–27 containing 
Cys25 and Cys27, neither bound nor entered the gastric cells, suggesting that 
a dimer formation of Tipα with one or two disulfide bonds is required for 
both specific binding to gastric cells and induction of TNF-α gene expression 
(Suganuma et al., 2008). A confocal laser scanning microscope analysis 
revealed that a significant amount of H. pylori Tipα is localized in the 
nucleus of the gastric cancer cells (Suganuma et al., 2008). Tipα was shown 
to activate NF-κB in mouse gastric epithelial cells MGT-40 and to induce in 
vitro transformation of v-H-ras transfected BALB/3T3 (Bhas 42) cells 
(Suganuma et al., 2005; Suganuma et al., 2006).  The DNA-binding activity 
of Tipα secreted from H. pylori was also demonstrated by the pull-down and 
surface plasmon resonance assays (Kuzuhara et al., 2007b). The recombinant 
Tipα (residues 21–192) also bound to TNF-α promoter sequences dose-
dependently and its DNA-binding affinity was much higher than del-Tipα 
(residues 28–192), which lacks the two cysteine residues Cys25 and Cys27 






























































































Very weak sequence homology between H. pylori Tipα and penicillin-
binding proteins from Gram-positive bacteria was detected, but the 
functional significance of this distant homology is unclear (Kuzuhara et al., 
2005). Prediction of the three-dimensional model of Tipα by sequence 
structure threading suggested that it may adopt a four-α-helical-bundle fold 
(Godlewska et al., 2008). However, a detailed three-dimensional structure of 
Tipα is required to provide a structural basis for better understanding of 
DNA-binding by Tipα and thus the carcinogenic mechanism of Tipα. In this 
study, we have determined the crystal structure of Tipα from H. pylori by the 
multiwavelength anomalous diffraction (MAD) method of X-ray 
crystallography. It reveals that H. pylori Tipα adopts a new fold for a DNA-
binding protein family and that the N-terminally truncated Tipα (residues 
28–192) exists as a dimer in the crystal. Site-directed mutagenesis suggests 
that a positively charged surface patch formed across the two monomers of 





2.2. Material and methods 
 
2.2.1. Protein expression and purification 
The H. pylori Tipα gene (HP0596) encoding the N-terminally truncated 
form (residues 28–192) was PCR-amplified and cloned into the expression 
vector pET-28b(+) (Novagen). This construct of the recombinant protein 
contains a hexa-histidine-containing 21-residue extra sequence 
(MGSSHHHHHH SSGLVPRGSH M) in front of the starting residue Pro28. 
It is identical to del-Tipα (Suganuma et al., 2005; Kuzuhara et al., 2007b). 
The recombinant protein substituted with SeMet was overexpressed in E. 
coli Rosetta2(DE3)pLysS cells using M9 culture medium supplemented with 
SeMet. Protein expression was induced by 0.5 mM isopropyl 1-thio-β-D-
galactopyranoside and the cells were incubated for an additional 24 h at 
30C after growth to the mid-long phase at 37C. The cells were lysed by 
sonication in a lysis buffer (50 mM Tris-HCl at pH 7.9, 500 mM NaCl, and 
10% (v/v) glycerol) containing 50 mM imidazole. The crude lysate was 
centrifuged at ~36,000 g for 60 min. The supernatant was applied to an 
affinity chromatography column of HiTrap Chelating HP (GE Healthcare). 




and the eluted sample was diluted tenfold with buffer A (20 mM sodium 
phosphate at pH 6.0). The diluted sample was applied to a Hitrap SP HP 
column (5 ml) (GE Healthcare), previously equilibrated with buffer A. Upon 
eluting with a gradient of NaCl in the same buffer, Tipα was eluted at 
360480 mM NaCl concentration. The next step was gel filtration on a 
HiLoad XK-16 Superdex 200 prep-grade column (GE Healthcare), 
previously equilibrated with 20 mM citric acid at pH 4.0 and 200 mM NaCl. 
The eluted protein was concentrated to 11 mg ml-1 for crystallization using 
an Amicon Ultra-15 centrifugal filter unit (Millipore). Dynamic light 
scattering experiments were performed on a DynaPro-801 instrument (Wyatt) 
at ~1 mg ml-1 protein dissolved in the same buffer used in gel filtration on 





2.2.2. Mutagenesis and electrophoretic mobility shift assay 
The mature Tipα (residues 21–192), containing Cys25 and Cys27, was 
mutated using the QuikChange site-directed mutagenesis kit (Stratagene) and 
the mutations were confirmed by DNA sequencing. The K102A/K104A 
double mutant was expressed and purified under the conditions identical to 
those for the wild-type. The double mutant showed a similar elution profile 
as the wild-type upon gel filtration. SDS-PAGE analysis indicated that the 
double mutant as well as the wild-type Tipα migrated as a dimer in the 
absence of β-mercaptoethanol but was present as a monomer in the presence 
of β-mercaptoethanol. We mixed 1.5 or 3.0 l of Tipα (3.7 g l-1) and 3.0 
l of a linear dsDNA with 545 base pairs (140 ng l-1), corresponding to the 
molar ratio of 10:1 or 20:1 for Tipα dimer to dsDNA. The reaction mixtures 
were incubated for 20 min at room temperature. Binding of Tipα to dsDNA 
was analyzed by 0.5 %(w/v) agarose gel electrophoresis in 1TAE buffer (45 
mM Tris-acetate at pH 8.3, 1 mM EDTA). DNA bands were visualized by 





2.2.3. Crystallization and data collection 
Crystals were grown by hanging-drop vapor diffusion method by mixing 
equal volumes of the protein solution and the reservoir solution (100 mM 
Tris-HCl at pH 7.0, 200 mM calcium acetate, and 20% (w/v) PEG 3000) 
(Figure 2-3). They were transferred to a cryoprotectant solution which 
contained 15% (v/v) glycerol in the reservoir solution. Two sets (SeMet I and 
SeMet II) of MAD data were collected at 100 K on an ADSC Quantum 315 
detector at the BL-5A experimental station of Photon Factory (PF), Japan 
and on an ADSC Quantum 210 CCD detector (Area Detector Systems 
Corporation, Poway, California) at the BL-4A experimental station of 
Pohang Light Source (PLS), Korea, respectively. The raw data were 
processed and scaled using the program suit HKL2000 (Otwinowski and 
Minor, 1997). The crystals belong to the space group P212121, with unit cell 
parameters of a = 53.52 Å, b = 67.11 Å, and c = 91.26 Å for the SeMet II 
(remote) data (Table 2-1). Two monomers of Tipα are present in the 
asymmetric unit, giving VM of 1.93 Å








































































































































































































































































































































































































































































































































Footnote to Table 2-1 
Values in parentheses refer to the highest resolution shells [2.80–2.70 Å for 
the SeMet I MAD data and 2.49–2.40 Å for the SeMet II (remote) data]. 
aRmerge = h i  I(h)i – <I(h)>  / h i I(h)i, where I(h)i is the intensity of the 
i-th measurement of reflection h and <I(h)> is the mean value of I(h) for all i 
measurements. 
bFigure of merit =  |  P(α) exp(iα) /  P(α) | , where α is the phase angle 





2.2.4. Structure solution and refinement 
Ten of the fourteen expected selenium atoms of the two monomers in 
each crystallographic asymmetric unit were located with the program 
SOLVE (Terwilliger and Berendzen, 1999), and the selenium sites were 
used to calculate and improve the phases with RESOLVE (Terwilliger, 
2003). The resulting electron density map was interpreted by the automatic 
model building program RESOLVE, which generated an initial model that 
accounted for ~37% of the residues in the polypeptide chain with much of 
the sequence assigned. Subsequent manual model building was conducted 
using the program COOT (Emsley and Cowtan, 2004). The model was 
refined with the program REFMAC (Murshudov et al., 1997), including the 
bulk solvent correction. Ten percent of the data were randomly set aside as 
the test data for the calculation of Rfree (Brünger, 1992). The program 
PROCHECK was used to assess the stereochemistry and to assign the 
secondary structure elements (Laskowski et al., 1993). Refinement statistics 









Table 2-2. Refinement statistics 
 
 
Footnotes to Table 2-2 
a Rwork =  | |Fobs| – |Fcalc| | /  |Fobs|, where Rfree is calculated for a randomly 
chosen 10% of reflections, which were not used for structure refinement, and 
Rwork is calculated for the remaining reflections.  
b Values obtained using PROCHECK. 
 
Refinement 
Data set SeMet II (remote) 
Resolution range (Å) 30.0–2.40 
No. of reflections (working/free set) 12,433 / 714 
No. of protein non-hydrogen atoms 2,391  
No. of water molecules 70 
Rwork/Rfree
a (%) 23.3 / 24.1 
R.m.s. deviations from ideal geometry   
Bond length (Å) 0.0067 
Bond angle () 1.15 
Average B-factor (Å2)  
Protein 41.1 
Water molecules 43.6 
Ramachandran plot for non-glycine and non-proline residuesb  
Most favorable regions (%) (chains A/B) 92.8 / 90.6 
Allowed regions (%) (chains A/B) 6.5 / 9.4 




2.3. Results and discussion 
 
2.3.1. Model quality and structure of Tipα monomer  
We have solved the crystal structure of H. pylori Tipα (residues 28–192) 
using selenomethionine (SeMet) MAD data. The model was refined against 
the SeMet II (remote) data (Table 2-2); it yielded Rwork and Rfree values of 
23.3% and 24.1% for 30.02.40 Å data, respectively. The model contains 
296 residues in two monomers of Tipα (residues 34–181 for both chains A 
and B) and 70 water molecules in the crystallographic asymmetric unit 
(Table 2-2). The missing residues of Tipα and the N-terminal fusion tag are 
probably disordered in the crystal and are invisible in the electron density 
map. An N-terminal loop region (residues 34–36 and 46–51 for chain A; 
residues 34–35 and 48–51 for chain B), a loop between β1 and α1 (residues 
62–63 for chain B), a loop between β2 and α2 (132–136 for chain B), and a 






A monomer of Tipα (residues 28–192) consists of four α-helices, three 
β-strands, and a number of loops. Each monomer is somewhat elongated and 
curved. It may be loosely divided into two structural domains (“mixed 
domain” and “helical domain”), with the longest helix α1 being shared 
between them and providing a platform for building the two structural 
domains (Figure 2-4). The first domain (“mixed domain”) consists of a 
central three-stranded antiparallel β-sheet (β1↑-β3↓-β2↑) that covers the N-
terminal half of the longest helix α1. A long N-terminal loop covers the other 
face of central β-sheet. The two β-strands β2 and β3 are inserted between 
helices α2 and α3. The other domain (“helical domain”) is a four-helix 
bundle formed of the helices α1 (the C-terminal half), α2, α3, and α4 (Figure 
2-5). The hydrophobic core of the bundle is formed by Val82, Leu90, Ile117, 
Leu152, Leu156, Val169, and Val173. The four-helix bundle is a common 
structural motif that occurs in many structural contexts and in proteins that 








































2.3.2. Structure of Tipα dimer 
The crystallographic asymmetric unit contains two monomers (chains A 
and B) of H. pylori Tipα. They show essentially the same conformation. 
Between chains A and B, the root-mean-square (r.m.s.) deviation is 0.56 Å 
for 148 Cα atom pairs and a maximum Cα deviation of 3.2 Å occurs at Ser49. 
The two monomers of Tipα in the asymmetric unit are related by a two-fold 
non-crystallographic symmetry and they form a tight dimer (Figure 2-6). The 
dimer formation buries an accessible surface area of 1,560 Å2. There are no 
other possible dimers in the crystal. Our dynamic light scattering 
measurement was consistent with the existence of recombinant Tipα as a 
dimer in the solution.  
The Tipα dimer in the asymmetric unit resembles a twisted doughnut 
(Figure 2-7), with dimensions of 52 Å × 46 Å × 25 Å. Contacts between the 
monomers are made through two distinct regions. The first is the long N-
terminal loop (residues 34–50 and 55–58) and a segment between strands β2 
and β3 (residues 130, 132, 135, 137, 139) in the “mixed domain.” The 
second is a segment between helices α1 and α2 (residues 81, 85, 88, 91, 92, 
94–99, 104–108, 110) in the “helical domain.” The interface area contributed 
by the “mixed domain” is nearly twice that contributed by the “helical 




diameter (Figure 2-7). If the N-terminal residues absent in our Tipα structure 
are assumed to be extended and to point toward each other in the bulk 
solvent, one or both of Cys25 and Cys27 could form one or two inter-chain 
disulfide bonds. It is likely that the resulting dimer structure of Tipα 
(residues 21–192) would not significantly deviate from that of del-Tipα 
(residues 28–192). 
Gel electrophoresis showed that the recombinant del-Tipα protein was 
monomeric without any influence of dithiothreitol (DTT), while the 
recombinant Tipα was a dimer in the absence of DTT and a monomer with 
DTT (Suganuma et al., 2005). This discrepancy between our observation of a 
stable dimer of del-Tipα in the crystal and the reported monomer of del-Tipα 
could be due to much different protein concentrations used in different 
experiments. Dimers of Tipα as well as del-Tipα that exist at high protein 
concentrations may dissociate into monomers at very low protein 
concentrations, if they are not stabilized by a disulfide bond. Thus, the inter-
chain disulfide bond(s) formed by Cys25 and Cys27 may be necessary to 
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2.3.3. Structural similarity searches 
A search for structural homologs of H. pylori Tipα monomer in the 
Protein Data Bank using the DALI server (Holm and Sander, 1996) revealed 
that there is no highly similar structure. The highest Z-score was only 5.7; it 
was obtained with the N-terminal domain (NTD) of Nab2 (residues 1–97) 
(PDB code 2V75) (Grant et al., 2008). The sequence identity between them 
is only 7% and the r.m.s. deviation is 3.0 Å for 71 Cα atoms in the α1–α2 
and α3–α4 regions of the Tipα “helical domain” and the α1–α4 region of 
Nab2 NTD. The arrangement of four α-helices in the “helical domain” of 
Tipα is similar to that of the first four α-helices in Nab2 NTD (Grant et al., 
2008). Nab2 NTD is largely helical with five α-helices and has no β-strand. 
Compared with the “helical domain” of Tipα, an extra fifth C-terminal helix 
α5 lies approximately antiparallel to the N-terminal helix α1 in Nab2 NTD 
(Figure 2-8). The helical fold of Nab2 NTD is similar to the PWI fold found 
in several other RNA-binding proteins (Grant et al., 2008). Other PWI fold 
proteins such as the U4/U6 small nuclear ribonucleoprotein, Prp3 (PDB code 
1X4Q) and SRm160-PWI motif (PDB code 1MP1) are also mostly helical 
(Szymczyna et al., 2003). Nab2 NTD mediates protein-protein interactions 
and there is no evidence that Nab2 NTD binds to nucleic acids (Grant et al., 




single-stranded (ss) RNA/DNA (Szymczyna et al., 2003). Furthermore, 
Nab2 NTD, Prp3, and SRm160-PWI motif are all monomeric. SRm160-PWI 
motif contains the characteristic Pro-Trp-Ile sequence in helix H1 
(Szymczyna et al., 2003), whereas Nab2 NTD and H. pylori Tipα lack such a 
sequence. All of these taken together indicate that the distant structural 
resemblance between the “helical domain” of Tipα and the PWI fold proteins 
such as Nab2 NTD is not likely to be functionally relevant. Therefore, our 
structure of H. pylori Tipα appears to represent the first structure of a novel 
DNA-binding protein family. 
The crystal structures of a truncated form of Tipα (TipαN34) in two 
different crystal forms were reported (Tosi et al., 2009). It has been 
suggested that crystal form I dimer at pH 4 is likely a crystallization artifact 
and that TipαN34 dimer observed in crystal from II at pH 8.5 is more likely 
to be relevant in solution. The latter structure is highly similar to our dimer 









































2.3.4. Insights into DNA-binding activity 
The Tipα dimer is toroidal, with the C-terminal part (residues 85–92) of 
helix α1 and the loop region (residues 46–52) immediately before strand β1 
contributing to form a hole of ~8 Å in diameter (Figure 2-7). Central holes in 
a number of toroidal proteins involved in DNA metabolism have a diameter 
of ~20–25 Å to hold ds-DNA (Hingorani and O’Donnel, 2000). In contrast, 
the central hole of Tipα dimer is too narrow to encircle ds-DNA. The surface 
electrostatic potential of Tipα dimer suggests that a positively charged 
surface region at the bottom of Tipα dimer in Figure 2-7, formed across two 
monomers by the loop between helices α1 and α2 (residues 96–106), could 
be important in DNA binding. To assess the role of this region in DNA 
binding, we have mutated two positively charged residues Lys102 and 
Lys104 into alanine. Electrophoretic mobility shift assay indicated that the 
dsDNA binding ability of the double mutant (K102A/K104A) was 
considerably diminished compared to the wild-type Tipα (Figure 2-9). This 
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dependent decrease of the dsDNA band intensity, whereas the double mutant 







2.3.5. Accession number 
Atomic coordinates and structure factors of H. pylori Tipα have been 
deposited in the Protein Data Bank (http://www.rcsb.org/pdb) under 






2.4. Conclusion  
 
In summary, I have determined the crystal structure of H. pylori Tipα 
(residues 28–192). It exists as a dimer in the crystal and its dimeric structure 
represents a novel scaffold for DNA-binding. Recently, a small molecule 
inhibitor of nucleophosmin oligomerization was found to inhibit 
proliferation of cancer cells (Qi et al., 2008). The structural information 
reported in this study can provide a starting point for discovering small 
molecule inhibitors that block homodimerization of H. pylori Tipα and thus 
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Structural Basis for Differential Transcription Activation by Enantiomeric 
Agonists of PPARγ and Crystal Structure of TNF-α-Inducing Protein (Tipα) 
from Helicobacter pylori 
 
PPARγ 거울상 이성질체 작용제에 의한 차등 전사 활성화에 대한 구조 연구 
및 헬리코박터 파이로리 유래 TNF-α-Inducing Protein (Tipα) 단백질에 
대한 결정 구조 연구 
 
퍼옥시좀 증식인자 활성화 수용체 감마 (PPARγ)는 핵 수용체 슈퍼 
패밀리의 구성원이다. 이것은 리간드에 의해 활성화되는 전사 인자로서 
지방 세포 분화와 제 2 형 당뇨병 및 염증 조절의 중요한 역할을 감당한다. 
수많은 PPARγ 작용제는 알파나선 H12 근방의 표준 리간드 결합 주머니에 
결합한다. 최근 연구를 통해서 PPARγ 의 대체 리간드 결합 부위가 
확인되었는데, 그것은 알파나선 H2'와 H3 사이의 오메가 루프 부근에 
위치하고 있다. 본 연구의 선행 연구를 통하여 두개의 최적화 된 거울상 
이성질체 PPARγ 리간드 (S35 및 R35)의 분자 비대칭성이 PPARγ 전사 
활성과 결합력, Cdk5 매개 PPARγ 273 번 세린 잔기 인산화 저해 활동도의 
차이를 나타나게 함을 발표하였다. R35 는 기존 방식의 PPARγ 작용제로 
강력하게 작용하지만 S35 는 상당한 혈당 흡수 포텐셜을 가지는 PPARγ 
인산화 억제제로 작용한다. 이러한 리간드의 차등 활동에 대한 구조적 기초 
제공을 위해 본 연구에서는 S35 와 R35 각각의 PPARγ 리간드 결합 도메인 
복합체의 결정 구조를 규명하였다. PPARγ 리간드 결합 도메인 복합체의 
구조는 이러한 거울상 이성질체 리간드의 결합 양식에서 상당한 차이를 




반면 S35 는 대체 리간드 결합 부위를 차지하여, 두 이성질체의 서로 다른 
행동 양식을 잘 설명한다. 이 연구 결과는 당뇨병 신약 후보로서 새로운 
세대의 PPARγ 리간드 개발에 유용한 환경을 제공할 것이다. 
 
헬리코박터 파일로리균의 감염은 위암을 포함한 위·십이지장 질환의 가장 
높은 위험 요인 중 하나이다. TNF-α 는 종양 촉진을 위해 필수적인 
사이토카인 중의 하나이며, 따라서 TNF-α 의 발현을 유도하는 헬리코박터 
파이로리균의 단백질은 인간의 위암 발생에 중요한 역할을 할 것으로 
예상된다. 헬리코박터 파이로리 26695 균주의 HP0596 유전자 생성물은 
TNF-α 유도 단백질 (Tipα)로 확인되었다. Tipα 는 이합체 상태로 
헬리코박터 파이로리균에서 분비된 후, 위 세포로 침투한다. 이 단백질은 
DNA 결합 활성을 갖는 것으로 나타났다. 본 연구에서는 헬리코박터 
파이로리균 Tipα 단백질의 삼차원 구조를 규명하였다. Tipα 단백질의 
단량체는 두 개의 구조적 도메인("혼합 도메인"과 "나선형 도메인")으로 
구성되어 있다. Tipα 단백질은 결정 구조 내에서 이합체 상태로 존재하고, 
이 이합체 구조는 DNA 결합을 위한 새로운 단백질 골격을 나타낸다. 
알파나선 α1 과 α2 사이의 루프에 의해 Tipα 단백질 이합체의 두 단량체를 




주요어: crystal structure / S35 / R35 / alternate ligand-binding site / Ω loop / 
peroxisome proliferator-activated receptor / type 2 diabetes / PPARγ agonist 
/ tumor necrosis factor-α inducing protein / Tipα / HP0596 / Helicobacter 
pylori / gastric cancer 
